Myeloma Minute: July 16, 2015
Is There a Tie Between Leisure Time Spent Sitting and Cancer Risks?
In his blog this week, IMF Chairman Dr. Brian Durie examines a new study in the July 2015 issue of “Cancer Epidemiology, Biomarkers & Prevention” suggesting that women who spend more leisure time sitting may be at a higher risk for multiple myeloma, breast and ovarian cancer. The higher risk was present even after taking into account BMI, physical activity, and other factors. The study found no association between sitting time and cancer risk in men. Click HERE to read his blog.
Calling All Researchers: Submit Your Applications for 2016 IMF Grants
The IMF awards Brian D. Novis Junior and Senior Research Grants each year to "provide much-needed funding support for research projects being conducted by the best and the brightest in our field," according to IMF President Susie Novis. Funding grants since 1994 to honor IMF Co-Founder Brian D. Novis, the IMF has awarded more than 140 grants in 13 countries, which have opened the doors to new ideas and major advancements in treatments. Applications for 2016 grants are due by August 3rd. To submit an application, click HERE.
*Applications are no longer being accepted.
New Drug Application Filed with FDA for Oral Proteasome Inhibitor
Takeda has filed for FDA approval of ixazomib, which could become the first oral proteasome inhibitor for treating multiple myeloma. The New Drug Application (NDA) for ixazomib is based on the results of the phase III TOURMALINE-MM1 trial, which compared ixazomib to placebo—both given in 772 patients with relapsed or refractory myeloma. “If approved, ixazomib, with the convenience of once-a-week oral administration as well as promising efficacy, should provide a very meaningful advance for our patients,” said Dr. Paul Richardson, Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center Institute Physician at Dana-Farber Cancer Institute. Click HERE to read the announcement.
Expanded Access Program Opens for Daratumumab
Janssen Biotech, Inc. has announced the opening of a daratumumab expanded access program (EAP) at up to 40 medical centers for eligible US myeloma patients who have received at least 3 prior lines of therapy (including a proteasome inhibitor and an immunomodulatory agent) or are double refractory to a proteasome inhibitor and an immunomodulatory agent. Daratumumab is currently an investigational human anti-CD38 monoclonal antibody treatment for multiple myeloma. To learn more about the EAP for daratumumab, contact the IMF InfoLine at (800) 452-2873 or email email@example.com.
Join the 2nd Annual Chek Fest Multiple Myeloma Golf Fundraiser
The 2nd Annual Chek Fest Multiple Myeloma Golf Fundraiser tournament is happening next Friday, July 24 at The Meadows Golf Club in Allendale, Michigan. The golf tournament is being organized by Scott Kowalczyk, who was diagnosed with multiple myeloma in 2012 and all proceeds will be donated to the IMF. Sign-up is available online, or on-site registration will be available at 11am the day of the event, prior to the 1pm start time. To donate, or sign-up, please visit the Chek Fest event page, HERE.
*This event is now closed